AstraZeneca | Cafepharma Message Boards | Pharma Sales, Device …
Oct 6, 2024 · Anonymous board for AstraZeneca. Even in these early responses, it’s clear that AI tools are already part of many people’s day-to-day work.
AstraZeneca | Cafepharma
Feb 20, 2026 · AstraZeneca has entered an agreement with China-based CSPC Pharmaceuticals to advance drug development programs targeting obesity and type 2 diabetes. The deal covers eight …
AstraZeneca | Cafepharma
Mar 6, 2026 · AstraZeneca has entered an agreement with China-based CSPC Pharmaceuticals to advance drug development programs targeting obesity and type 2 diabetes. The deal covers eight …
January 26 2026 - Biopharma layoffs surged last year, but 2026 is a ...
Jan 26, 2026 · Signs of renewed momentum are emerging across the sector, as companies balance the legacy of layoffs and restructuring with clinical progress, IPO hopes, and growing use of …
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Anonymous discussion boards for pharmaceutical sales, medical/device sales, lab/diagnostics sales
January 14 2026 - JPM26: AstraZeneca's $80B revenue target 'very …
Jan 14, 2026 · Confidence is on full display at JPM, as companies talk up revenue targets, pipeline momentum, and dealmaking strength—tempered by ongoing regulatory and pricing realities.JPM26: …
Cafepharma - Home | pharma sales, device sales, lab sales | Cafepharma
1 day ago · Clinical data, regulatory approvals and leadership changes lead today’s headlines, alongside rare disease advances, vaccine manufacturing partnerships and continued restructuring across the …
AstraZeneca Seals $1.2B Obesity and Metabolic Disease Pipeline Deal ...
Feb 11, 2026 · AstraZeneca has entered an agreement with China-based CSPC Pharmaceuticals to advance drug development programs targeting obesity and type 2 diabetes. The deal covers eight …
AstraZeneca sets sights on 25+ blockbusters by 2030 to fuel $80B ...
Feb 10, 2026 · After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030” revenue target, outlining a roadmap to have more than 25 …
Multiply Labs partners with AstraZeneca to automate cell therapy ...
Jan 27, 2026 · Multiply Labs Inc. today announced an agreement with AstraZeneca to evaluate the potential for applying good manufacturing practice, or GMP-ready, robotic systems to commercial …